1. Home
  2. NKTR vs IRON Comparison

NKTR vs IRON Comparison

Compare NKTR & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nektar Therapeutics

NKTR

Nektar Therapeutics

N/A

Current Price

$73.12

Market Cap

2.1B

Sector

Health Care

ML Signal

N/A

Logo Disc Medicine Inc.

IRON

Disc Medicine Inc.

N/A

Current Price

$59.82

Market Cap

2.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NKTR
IRON
Founded
1990
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.3B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
NKTR
IRON
Price
$73.12
$59.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
11
Target Price
$130.00
$103.18
AVG Volume (30 Days)
782.4K
473.9K
Earning Date
03-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$307,711,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$283.52
P/E Ratio
N/A
N/A
Revenue Growth
86.00
N/A
52 Week Low
$0.43
$30.82
52 Week High
$77.00
$99.50

Technical Indicators

Market Signals
Indicator
NKTR
IRON
Relative Strength Index (RSI) 61.90 45.02
Support Level $52.99 $57.81
Resistance Level $75.96 $61.93
Average True Range (ATR) 3.59 2.72
MACD -0.63 0.36
Stochastic Oscillator 88.37 42.73

Price Performance

Historical Comparison
NKTR
IRON

About NKTR Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

About IRON Disc Medicine Inc.

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Share on Social Networks: